Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Share-based Compensation (2016 - 2025)

Regenxbio has reported Share-based Compensation over the past 12 years, most recently at $8.4 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $8.4 million for Q4 2025, down 12.23% from a year ago — trailing twelve months through Dec 2025 was $34.6 million (down 10.14% YoY), and the annual figure for FY2025 was $34.6 million, down 10.14%.
  • Share-based Compensation for Q4 2025 was $8.4 million at Regenxbio, down from $9.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RGNX hit a ceiling of $11.2 million in Q1 2023 and a floor of $8.3 million in Q4 2023.
  • Median Share-based Compensation over the past 5 years was $9.7 million (2021), compared with a mean of $9.6 million.
  • Biggest five-year swings in Share-based Compensation: increased 23.74% in 2021 and later decreased 14.31% in 2024.
  • Regenxbio's Share-based Compensation stood at $9.2 million in 2021, then rose by 2.69% to $9.4 million in 2022, then decreased by 11.37% to $8.3 million in 2023, then rose by 14.44% to $9.5 million in 2024, then fell by 12.23% to $8.4 million in 2025.
  • The last three reported values for Share-based Compensation were $8.4 million (Q4 2025), $9.0 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.